Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia
Health Canada authorizes ProMetic BioSciences to begin Ib/II trial of PBI-1402 for anemia
March 24th, 2006
ProMetic BioSciences Inc. announced that it has received authorization from the Therapeutic Products Directorate of Health Canada to begin a phase Ib/II clinical trial of PBI-1402, its novel therapeutic compound in development to treat patients with anemia. The company plans to study the safety and efficacy of PBI-1402 in up to 30 cancer patients undergoing chemotherapy and suffering from anemia. This clinical trial will be undertaken at Maisonneuve-Rosemont Hospital, in Montreal, under the supervision of Drs. Denis-Claude Roy (hematologist) and Julie Beaudet (oncologist). "Following the results obtained during the phase I trial, displaying an...
Source: Drug Week (2006-03-24)
|
